nodes	percent_of_prediction	percent_of_DWPC	metapath
Azelastine—CYP1A1—Dacarbazine—pancreatic cancer	0.0503	0.0633	CbGbCtD
Azelastine—CYP2A6—Tamoxifen—pancreatic cancer	0.0469	0.059	CbGbCtD
Azelastine—CYP1A1—Tamoxifen—pancreatic cancer	0.04	0.0504	CbGbCtD
Azelastine—CYP2E1—Dacarbazine—pancreatic cancer	0.0389	0.0489	CbGbCtD
Azelastine—KCNH2—Sunitinib—pancreatic cancer	0.0351	0.0442	CbGbCtD
Azelastine—CYP2A6—Fluorouracil—pancreatic cancer	0.0345	0.0435	CbGbCtD
Azelastine—CYP1A1—Erlotinib—pancreatic cancer	0.034	0.0429	CbGbCtD
Azelastine—CYP2E1—Tamoxifen—pancreatic cancer	0.0309	0.0389	CbGbCtD
Azelastine—CYP2B6—Tamoxifen—pancreatic cancer	0.0305	0.0384	CbGbCtD
Azelastine—CYP3A5—Tamoxifen—pancreatic cancer	0.024	0.0302	CbGbCtD
Azelastine—CYP2B6—Irinotecan—pancreatic cancer	0.0234	0.0295	CbGbCtD
Azelastine—CYP2C8—Tamoxifen—pancreatic cancer	0.0231	0.0291	CbGbCtD
Azelastine—CYP1A2—Dacarbazine—pancreatic cancer	0.0225	0.0283	CbGbCtD
Azelastine—CYP3A5—Erlotinib—pancreatic cancer	0.0204	0.0257	CbGbCtD
Azelastine—CYP2C8—Erlotinib—pancreatic cancer	0.0196	0.0247	CbGbCtD
Azelastine—CYP2C19—Tamoxifen—pancreatic cancer	0.0194	0.0244	CbGbCtD
Azelastine—CYP3A5—Irinotecan—pancreatic cancer	0.0184	0.0232	CbGbCtD
Azelastine—CYP1A2—Tamoxifen—pancreatic cancer	0.0179	0.0225	CbGbCtD
Azelastine—CYP2C8—Fluorouracil—pancreatic cancer	0.017	0.0214	CbGbCtD
Azelastine—CYP2C9—Tamoxifen—pancreatic cancer	0.0161	0.0203	CbGbCtD
Azelastine—ABCB1—Tamoxifen—pancreatic cancer	0.0156	0.0197	CbGbCtD
Azelastine—CYP1A2—Erlotinib—pancreatic cancer	0.0152	0.0191	CbGbCtD
Azelastine—CYP2D6—Tamoxifen—pancreatic cancer	0.0147	0.0185	CbGbCtD
Azelastine—CYP3A5—Docetaxel—pancreatic cancer	0.0135	0.017	CbGbCtD
Azelastine—ABCB1—Gemcitabine—pancreatic cancer	0.0135	0.017	CbGbCtD
Azelastine—CYP3A5—Sunitinib—pancreatic cancer	0.0135	0.0169	CbGbCtD
Azelastine—ABCB1—Erlotinib—pancreatic cancer	0.0133	0.0167	CbGbCtD
Azelastine—CYP1A2—Fluorouracil—pancreatic cancer	0.0132	0.0166	CbGbCtD
Azelastine—CYP2B6—Doxorubicin—pancreatic cancer	0.0128	0.0161	CbGbCtD
Azelastine—CYP2D6—Erlotinib—pancreatic cancer	0.0125	0.0158	CbGbCtD
Azelastine—ABCB1—Irinotecan—pancreatic cancer	0.012	0.0151	CbGbCtD
Azelastine—CYP2C9—Fluorouracil—pancreatic cancer	0.0119	0.0149	CbGbCtD
Azelastine—CYP3A4—Tamoxifen—pancreatic cancer	0.00937	0.0118	CbGbCtD
Azelastine—ABCB1—Docetaxel—pancreatic cancer	0.0088	0.0111	CbGbCtD
Azelastine—ABCB1—Sunitinib—pancreatic cancer	0.00876	0.011	CbGbCtD
Azelastine—CYP3A4—Erlotinib—pancreatic cancer	0.00797	0.01	CbGbCtD
Azelastine—CYP3A4—Irinotecan—pancreatic cancer	0.00719	0.00906	CbGbCtD
Azelastine—ABCB1—Doxorubicin—pancreatic cancer	0.00656	0.00826	CbGbCtD
Azelastine—CYP2D6—Doxorubicin—pancreatic cancer	0.00618	0.00778	CbGbCtD
Azelastine—CYP3A4—Docetaxel—pancreatic cancer	0.00527	0.00664	CbGbCtD
Azelastine—CYP3A4—Sunitinib—pancreatic cancer	0.00525	0.00661	CbGbCtD
Azelastine—CYP3A4—Doxorubicin—pancreatic cancer	0.00393	0.00495	CbGbCtD
Azelastine—Pruritus—Erlotinib—pancreatic cancer	0.000265	0.00171	CcSEcCtD
Azelastine—Discomfort—Fluorouracil—pancreatic cancer	0.000263	0.0017	CcSEcCtD
Azelastine—Anaphylactoid reaction—Epirubicin—pancreatic cancer	0.000261	0.00169	CcSEcCtD
Azelastine—Eczema—Doxorubicin—pancreatic cancer	0.000261	0.00168	CcSEcCtD
Azelastine—Rhinitis—Docetaxel—pancreatic cancer	0.00026	0.00168	CcSEcCtD
Azelastine—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.00026	0.00168	CcSEcCtD
Azelastine—Eye pain—Doxorubicin—pancreatic cancer	0.000259	0.00167	CcSEcCtD
Azelastine—Diarrhoea—Tamoxifen—pancreatic cancer	0.000259	0.00167	CcSEcCtD
Azelastine—Hypoaesthesia—Docetaxel—pancreatic cancer	0.000258	0.00167	CcSEcCtD
Azelastine—Infection—Gemcitabine—pancreatic cancer	0.000258	0.00166	CcSEcCtD
Azelastine—Confusional state—Fluorouracil—pancreatic cancer	0.000258	0.00166	CcSEcCtD
Azelastine—Pharyngitis—Docetaxel—pancreatic cancer	0.000258	0.00166	CcSEcCtD
Azelastine—Abdominal pain—Sunitinib—pancreatic cancer	0.000256	0.00165	CcSEcCtD
Azelastine—Body temperature increased—Sunitinib—pancreatic cancer	0.000256	0.00165	CcSEcCtD
Azelastine—Diarrhoea—Erlotinib—pancreatic cancer	0.000256	0.00165	CcSEcCtD
Azelastine—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.000255	0.00165	CcSEcCtD
Azelastine—Infection—Fluorouracil—pancreatic cancer	0.000254	0.00164	CcSEcCtD
Azelastine—Visual impairment—Docetaxel—pancreatic cancer	0.00025	0.00161	CcSEcCtD
Azelastine—Dizziness—Tamoxifen—pancreatic cancer	0.00025	0.00161	CcSEcCtD
Azelastine—Tachycardia—Fluorouracil—pancreatic cancer	0.000249	0.00161	CcSEcCtD
Azelastine—Increased appetite—Doxorubicin—pancreatic cancer	0.000249	0.00161	CcSEcCtD
Azelastine—Dizziness—Erlotinib—pancreatic cancer	0.000247	0.0016	CcSEcCtD
Azelastine—Face oedema—Epirubicin—pancreatic cancer	0.000244	0.00158	CcSEcCtD
Azelastine—Eye disorder—Docetaxel—pancreatic cancer	0.000243	0.00156	CcSEcCtD
Azelastine—Anaphylactoid reaction—Doxorubicin—pancreatic cancer	0.000242	0.00156	CcSEcCtD
Azelastine—Flushing—Docetaxel—pancreatic cancer	0.000241	0.00155	CcSEcCtD
Azelastine—Vomiting—Tamoxifen—pancreatic cancer	0.00024	0.00155	CcSEcCtD
Azelastine—Paraesthesia—Irinotecan—pancreatic cancer	0.000239	0.00154	CcSEcCtD
Azelastine—Hypersensitivity—Sunitinib—pancreatic cancer	0.000239	0.00154	CcSEcCtD
Azelastine—Rash—Tamoxifen—pancreatic cancer	0.000238	0.00154	CcSEcCtD
Azelastine—Dermatitis—Tamoxifen—pancreatic cancer	0.000238	0.00154	CcSEcCtD
Azelastine—Vomiting—Erlotinib—pancreatic cancer	0.000238	0.00153	CcSEcCtD
Azelastine—Dyspnoea—Irinotecan—pancreatic cancer	0.000238	0.00153	CcSEcCtD
Azelastine—Somnolence—Irinotecan—pancreatic cancer	0.000237	0.00153	CcSEcCtD
Azelastine—Headache—Tamoxifen—pancreatic cancer	0.000237	0.00153	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000237	0.00153	CcSEcCtD
Azelastine—Rash—Erlotinib—pancreatic cancer	0.000236	0.00152	CcSEcCtD
Azelastine—Dermatitis—Erlotinib—pancreatic cancer	0.000236	0.00152	CcSEcCtD
Azelastine—Headache—Erlotinib—pancreatic cancer	0.000234	0.00151	CcSEcCtD
Azelastine—Paraesthesia—Gemcitabine—pancreatic cancer	0.000233	0.0015	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000233	0.0015	CcSEcCtD
Azelastine—Asthenia—Sunitinib—pancreatic cancer	0.000232	0.0015	CcSEcCtD
Azelastine—Dyspnoea—Gemcitabine—pancreatic cancer	0.000232	0.00149	CcSEcCtD
Azelastine—Somnolence—Gemcitabine—pancreatic cancer	0.000231	0.00149	CcSEcCtD
Azelastine—Fatigue—Irinotecan—pancreatic cancer	0.00023	0.00148	CcSEcCtD
Azelastine—Paraesthesia—Fluorouracil—pancreatic cancer	0.000229	0.00148	CcSEcCtD
Azelastine—Pruritus—Sunitinib—pancreatic cancer	0.000229	0.00148	CcSEcCtD
Azelastine—Pain—Irinotecan—pancreatic cancer	0.000228	0.00147	CcSEcCtD
Azelastine—Constipation—Irinotecan—pancreatic cancer	0.000228	0.00147	CcSEcCtD
Azelastine—Dyspnoea—Fluorouracil—pancreatic cancer	0.000228	0.00147	CcSEcCtD
Azelastine—Somnolence—Fluorouracil—pancreatic cancer	0.000227	0.00146	CcSEcCtD
Azelastine—Nasopharyngitis—Epirubicin—pancreatic cancer	0.000226	0.00146	CcSEcCtD
Azelastine—Face oedema—Doxorubicin—pancreatic cancer	0.000226	0.00146	CcSEcCtD
Azelastine—Nausea—Tamoxifen—pancreatic cancer	0.000225	0.00145	CcSEcCtD
Azelastine—Fatigue—Gemcitabine—pancreatic cancer	0.000224	0.00144	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.000223	0.00144	CcSEcCtD
Azelastine—Pain—Gemcitabine—pancreatic cancer	0.000222	0.00143	CcSEcCtD
Azelastine—Constipation—Gemcitabine—pancreatic cancer	0.000222	0.00143	CcSEcCtD
Azelastine—Nausea—Erlotinib—pancreatic cancer	0.000222	0.00143	CcSEcCtD
Azelastine—Diarrhoea—Sunitinib—pancreatic cancer	0.000222	0.00143	CcSEcCtD
Azelastine—Dysgeusia—Docetaxel—pancreatic cancer	0.000221	0.00143	CcSEcCtD
Azelastine—Feeling abnormal—Irinotecan—pancreatic cancer	0.00022	0.00142	CcSEcCtD
Azelastine—Asthma—Epirubicin—pancreatic cancer	0.000219	0.00141	CcSEcCtD
Azelastine—Back pain—Docetaxel—pancreatic cancer	0.000219	0.00141	CcSEcCtD
Azelastine—Pain—Fluorouracil—pancreatic cancer	0.000218	0.00141	CcSEcCtD
Azelastine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000218	0.00141	CcSEcCtD
Azelastine—Dizziness—Sunitinib—pancreatic cancer	0.000214	0.00138	CcSEcCtD
Azelastine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000214	0.00138	CcSEcCtD
Azelastine—Abdominal pain—Irinotecan—pancreatic cancer	0.000211	0.00136	CcSEcCtD
Azelastine—Body temperature increased—Irinotecan—pancreatic cancer	0.000211	0.00136	CcSEcCtD
Azelastine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000211	0.00136	CcSEcCtD
Azelastine—Bronchitis—Epirubicin—pancreatic cancer	0.00021	0.00136	CcSEcCtD
Azelastine—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000209	0.00135	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000206	0.00133	CcSEcCtD
Azelastine—Vomiting—Sunitinib—pancreatic cancer	0.000206	0.00133	CcSEcCtD
Azelastine—Body temperature increased—Gemcitabine—pancreatic cancer	0.000205	0.00132	CcSEcCtD
Azelastine—Rash—Sunitinib—pancreatic cancer	0.000204	0.00132	CcSEcCtD
Azelastine—Dermatitis—Sunitinib—pancreatic cancer	0.000204	0.00132	CcSEcCtD
Azelastine—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000203	0.00131	CcSEcCtD
Azelastine—Headache—Sunitinib—pancreatic cancer	0.000203	0.00131	CcSEcCtD
Azelastine—Asthma—Doxorubicin—pancreatic cancer	0.000202	0.00131	CcSEcCtD
Azelastine—Pollakiuria—Epirubicin—pancreatic cancer	0.000202	0.0013	CcSEcCtD
Azelastine—Body temperature increased—Fluorouracil—pancreatic cancer	0.000202	0.0013	CcSEcCtD
Azelastine—Palpitations—Docetaxel—pancreatic cancer	0.0002	0.00129	CcSEcCtD
Azelastine—Weight increased—Epirubicin—pancreatic cancer	0.000199	0.00128	CcSEcCtD
Azelastine—Cough—Docetaxel—pancreatic cancer	0.000197	0.00127	CcSEcCtD
Azelastine—Hypersensitivity—Irinotecan—pancreatic cancer	0.000197	0.00127	CcSEcCtD
Azelastine—Hypertension—Docetaxel—pancreatic cancer	0.000195	0.00126	CcSEcCtD
Azelastine—Bronchitis—Doxorubicin—pancreatic cancer	0.000195	0.00126	CcSEcCtD
Azelastine—Chest pain—Docetaxel—pancreatic cancer	0.000192	0.00124	CcSEcCtD
Azelastine—Myalgia—Docetaxel—pancreatic cancer	0.000192	0.00124	CcSEcCtD
Azelastine—Nausea—Sunitinib—pancreatic cancer	0.000192	0.00124	CcSEcCtD
Azelastine—Asthenia—Irinotecan—pancreatic cancer	0.000191	0.00123	CcSEcCtD
Azelastine—Conjunctivitis—Epirubicin—pancreatic cancer	0.00019	0.00122	CcSEcCtD
Azelastine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000188	0.00121	CcSEcCtD
Azelastine—Dry mouth—Docetaxel—pancreatic cancer	0.000188	0.00121	CcSEcCtD
Azelastine—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000188	0.00121	CcSEcCtD
Azelastine—Pollakiuria—Doxorubicin—pancreatic cancer	0.000187	0.00121	CcSEcCtD
Azelastine—Asthenia—Gemcitabine—pancreatic cancer	0.000186	0.0012	CcSEcCtD
Azelastine—Haematuria—Epirubicin—pancreatic cancer	0.000186	0.0012	CcSEcCtD
Azelastine—Confusional state—Docetaxel—pancreatic cancer	0.000186	0.0012	CcSEcCtD
Azelastine—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000184	0.00119	CcSEcCtD
Azelastine—Weight increased—Doxorubicin—pancreatic cancer	0.000184	0.00119	CcSEcCtD
Azelastine—Epistaxis—Epirubicin—pancreatic cancer	0.000184	0.00119	CcSEcCtD
Azelastine—Pruritus—Gemcitabine—pancreatic cancer	0.000184	0.00119	CcSEcCtD
Azelastine—Infection—Docetaxel—pancreatic cancer	0.000183	0.00118	CcSEcCtD
Azelastine—Sinusitis—Epirubicin—pancreatic cancer	0.000183	0.00118	CcSEcCtD
Azelastine—Diarrhoea—Irinotecan—pancreatic cancer	0.000182	0.00118	CcSEcCtD
Azelastine—Pruritus—Fluorouracil—pancreatic cancer	0.000181	0.00117	CcSEcCtD
Azelastine—Tachycardia—Docetaxel—pancreatic cancer	0.00018	0.00116	CcSEcCtD
Azelastine—Diarrhoea—Gemcitabine—pancreatic cancer	0.000178	0.00115	CcSEcCtD
Azelastine—Dizziness—Irinotecan—pancreatic cancer	0.000176	0.00114	CcSEcCtD
Azelastine—Rhinitis—Epirubicin—pancreatic cancer	0.000175	0.00113	CcSEcCtD
Azelastine—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000175	0.00113	CcSEcCtD
Azelastine—Diarrhoea—Fluorouracil—pancreatic cancer	0.000175	0.00113	CcSEcCtD
Azelastine—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000174	0.00112	CcSEcCtD
Azelastine—Pharyngitis—Epirubicin—pancreatic cancer	0.000174	0.00112	CcSEcCtD
Azelastine—Haematuria—Doxorubicin—pancreatic cancer	0.000172	0.00111	CcSEcCtD
Azelastine—Epistaxis—Doxorubicin—pancreatic cancer	0.00017	0.0011	CcSEcCtD
Azelastine—Vomiting—Irinotecan—pancreatic cancer	0.00017	0.00109	CcSEcCtD
Azelastine—Sinusitis—Doxorubicin—pancreatic cancer	0.000169	0.00109	CcSEcCtD
Azelastine—Dizziness—Fluorouracil—pancreatic cancer	0.000169	0.00109	CcSEcCtD
Azelastine—Visual impairment—Epirubicin—pancreatic cancer	0.000169	0.00109	CcSEcCtD
Azelastine—Rash—Irinotecan—pancreatic cancer	0.000168	0.00108	CcSEcCtD
Azelastine—Dermatitis—Irinotecan—pancreatic cancer	0.000168	0.00108	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000168	0.00108	CcSEcCtD
Azelastine—Headache—Irinotecan—pancreatic cancer	0.000167	0.00108	CcSEcCtD
Azelastine—Paraesthesia—Docetaxel—pancreatic cancer	0.000166	0.00107	CcSEcCtD
Azelastine—Vomiting—Gemcitabine—pancreatic cancer	0.000165	0.00107	CcSEcCtD
Azelastine—Dyspnoea—Docetaxel—pancreatic cancer	0.000164	0.00106	CcSEcCtD
Azelastine—Somnolence—Docetaxel—pancreatic cancer	0.000164	0.00106	CcSEcCtD
Azelastine—Rash—Gemcitabine—pancreatic cancer	0.000164	0.00106	CcSEcCtD
Azelastine—Dermatitis—Gemcitabine—pancreatic cancer	0.000164	0.00106	CcSEcCtD
Azelastine—Eye disorder—Epirubicin—pancreatic cancer	0.000164	0.00106	CcSEcCtD
Azelastine—Headache—Gemcitabine—pancreatic cancer	0.000163	0.00105	CcSEcCtD
Azelastine—Flushing—Epirubicin—pancreatic cancer	0.000162	0.00105	CcSEcCtD
Azelastine—Vomiting—Fluorouracil—pancreatic cancer	0.000162	0.00105	CcSEcCtD
Azelastine—Rhinitis—Doxorubicin—pancreatic cancer	0.000162	0.00105	CcSEcCtD
Azelastine—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000161	0.00104	CcSEcCtD
Azelastine—Rash—Fluorouracil—pancreatic cancer	0.000161	0.00104	CcSEcCtD
Azelastine—Dermatitis—Fluorouracil—pancreatic cancer	0.000161	0.00104	CcSEcCtD
Azelastine—Pharyngitis—Doxorubicin—pancreatic cancer	0.000161	0.00104	CcSEcCtD
Azelastine—Headache—Fluorouracil—pancreatic cancer	0.00016	0.00103	CcSEcCtD
Azelastine—Fatigue—Docetaxel—pancreatic cancer	0.000159	0.00103	CcSEcCtD
Azelastine—Nausea—Irinotecan—pancreatic cancer	0.000158	0.00102	CcSEcCtD
Azelastine—Pain—Docetaxel—pancreatic cancer	0.000158	0.00102	CcSEcCtD
Azelastine—Constipation—Docetaxel—pancreatic cancer	0.000158	0.00102	CcSEcCtD
Azelastine—Visual impairment—Doxorubicin—pancreatic cancer	0.000156	0.00101	CcSEcCtD
Azelastine—Nausea—Gemcitabine—pancreatic cancer	0.000154	0.000995	CcSEcCtD
Azelastine—Feeling abnormal—Docetaxel—pancreatic cancer	0.000152	0.00098	CcSEcCtD
Azelastine—Nausea—Fluorouracil—pancreatic cancer	0.000152	0.000979	CcSEcCtD
Azelastine—Eye disorder—Doxorubicin—pancreatic cancer	0.000151	0.000976	CcSEcCtD
Azelastine—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000151	0.000973	CcSEcCtD
Azelastine—Flushing—Doxorubicin—pancreatic cancer	0.00015	0.00097	CcSEcCtD
Azelastine—Tension—Epirubicin—pancreatic cancer	0.00015	0.000965	CcSEcCtD
Azelastine—Dysgeusia—Epirubicin—pancreatic cancer	0.000149	0.000963	CcSEcCtD
Azelastine—Nervousness—Epirubicin—pancreatic cancer	0.000148	0.000955	CcSEcCtD
Azelastine—Back pain—Epirubicin—pancreatic cancer	0.000147	0.000951	CcSEcCtD
Azelastine—Body temperature increased—Docetaxel—pancreatic cancer	0.000146	0.00094	CcSEcCtD
Azelastine—Abdominal pain—Docetaxel—pancreatic cancer	0.000146	0.00094	CcSEcCtD
Azelastine—Vision blurred—Epirubicin—pancreatic cancer	0.000144	0.000926	CcSEcCtD
Azelastine—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000141	0.000912	CcSEcCtD
Azelastine—Agitation—Epirubicin—pancreatic cancer	0.00014	0.000903	CcSEcCtD
Azelastine—Tension—Doxorubicin—pancreatic cancer	0.000138	0.000892	CcSEcCtD
Azelastine—Dysgeusia—Doxorubicin—pancreatic cancer	0.000138	0.000891	CcSEcCtD
Azelastine—Malaise—Epirubicin—pancreatic cancer	0.000137	0.000886	CcSEcCtD
Azelastine—Nervousness—Doxorubicin—pancreatic cancer	0.000137	0.000883	CcSEcCtD
Azelastine—Vertigo—Epirubicin—pancreatic cancer	0.000137	0.000883	CcSEcCtD
Azelastine—Back pain—Doxorubicin—pancreatic cancer	0.000136	0.00088	CcSEcCtD
Azelastine—Hypersensitivity—Docetaxel—pancreatic cancer	0.000136	0.000876	CcSEcCtD
Azelastine—Palpitations—Epirubicin—pancreatic cancer	0.000135	0.000869	CcSEcCtD
Azelastine—Cough—Epirubicin—pancreatic cancer	0.000133	0.000858	CcSEcCtD
Azelastine—Vision blurred—Doxorubicin—pancreatic cancer	0.000133	0.000857	CcSEcCtD
Azelastine—Asthenia—Docetaxel—pancreatic cancer	0.000132	0.000853	CcSEcCtD
Azelastine—Hypertension—Epirubicin—pancreatic cancer	0.000132	0.000849	CcSEcCtD
Azelastine—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000131	0.000844	CcSEcCtD
Azelastine—Pruritus—Docetaxel—pancreatic cancer	0.00013	0.000841	CcSEcCtD
Azelastine—Chest pain—Epirubicin—pancreatic cancer	0.00013	0.000837	CcSEcCtD
Azelastine—Myalgia—Epirubicin—pancreatic cancer	0.00013	0.000837	CcSEcCtD
Azelastine—Agitation—Doxorubicin—pancreatic cancer	0.00013	0.000836	CcSEcCtD
Azelastine—Anxiety—Epirubicin—pancreatic cancer	0.000129	0.000834	CcSEcCtD
Azelastine—Discomfort—Epirubicin—pancreatic cancer	0.000128	0.000827	CcSEcCtD
Azelastine—Malaise—Doxorubicin—pancreatic cancer	0.000127	0.00082	CcSEcCtD
Azelastine—Dry mouth—Epirubicin—pancreatic cancer	0.000127	0.000818	CcSEcCtD
Azelastine—Vertigo—Doxorubicin—pancreatic cancer	0.000127	0.000817	CcSEcCtD
Azelastine—Diarrhoea—Docetaxel—pancreatic cancer	0.000126	0.000814	CcSEcCtD
Azelastine—Confusional state—Epirubicin—pancreatic cancer	0.000125	0.000809	CcSEcCtD
Azelastine—Palpitations—Doxorubicin—pancreatic cancer	0.000125	0.000804	CcSEcCtD
Azelastine—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000124	0.000802	CcSEcCtD
Azelastine—Infection—Epirubicin—pancreatic cancer	0.000124	0.000797	CcSEcCtD
Azelastine—Cough—Doxorubicin—pancreatic cancer	0.000123	0.000794	CcSEcCtD
Azelastine—Dizziness—Docetaxel—pancreatic cancer	0.000122	0.000786	CcSEcCtD
Azelastine—Hypertension—Doxorubicin—pancreatic cancer	0.000122	0.000785	CcSEcCtD
Azelastine—Tachycardia—Epirubicin—pancreatic cancer	0.000121	0.000783	CcSEcCtD
Azelastine—Chest pain—Doxorubicin—pancreatic cancer	0.00012	0.000774	CcSEcCtD
Azelastine—Myalgia—Doxorubicin—pancreatic cancer	0.00012	0.000774	CcSEcCtD
Azelastine—Anxiety—Doxorubicin—pancreatic cancer	0.00012	0.000772	CcSEcCtD
Azelastine—Discomfort—Doxorubicin—pancreatic cancer	0.000119	0.000765	CcSEcCtD
Azelastine—Dry mouth—Doxorubicin—pancreatic cancer	0.000117	0.000757	CcSEcCtD
Azelastine—Vomiting—Docetaxel—pancreatic cancer	0.000117	0.000756	CcSEcCtD
Azelastine—Rash—Docetaxel—pancreatic cancer	0.000116	0.00075	CcSEcCtD
Azelastine—Dermatitis—Docetaxel—pancreatic cancer	0.000116	0.000749	CcSEcCtD
Azelastine—Confusional state—Doxorubicin—pancreatic cancer	0.000116	0.000748	CcSEcCtD
Azelastine—Headache—Docetaxel—pancreatic cancer	0.000116	0.000745	CcSEcCtD
Azelastine—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000115	0.000742	CcSEcCtD
Azelastine—Infection—Doxorubicin—pancreatic cancer	0.000114	0.000737	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000113	0.000731	CcSEcCtD
Azelastine—Tachycardia—Doxorubicin—pancreatic cancer	0.000112	0.000724	CcSEcCtD
Azelastine—Paraesthesia—Epirubicin—pancreatic cancer	0.000112	0.00072	CcSEcCtD
Azelastine—Dyspnoea—Epirubicin—pancreatic cancer	0.000111	0.000715	CcSEcCtD
Azelastine—Somnolence—Epirubicin—pancreatic cancer	0.000111	0.000713	CcSEcCtD
Azelastine—Nausea—Docetaxel—pancreatic cancer	0.00011	0.000706	CcSEcCtD
Azelastine—Fatigue—Epirubicin—pancreatic cancer	0.000107	0.000692	CcSEcCtD
Azelastine—Pain—Epirubicin—pancreatic cancer	0.000106	0.000686	CcSEcCtD
Azelastine—Constipation—Epirubicin—pancreatic cancer	0.000106	0.000686	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000105	0.000676	CcSEcCtD
Azelastine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000103	0.000666	CcSEcCtD
Azelastine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000103	0.000662	CcSEcCtD
Azelastine—Feeling abnormal—Epirubicin—pancreatic cancer	0.000102	0.000661	CcSEcCtD
Azelastine—Somnolence—Doxorubicin—pancreatic cancer	0.000102	0.00066	CcSEcCtD
Azelastine—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000102	0.000656	CcSEcCtD
Azelastine—Fatigue—Doxorubicin—pancreatic cancer	9.92e-05	0.00064	CcSEcCtD
Azelastine—Constipation—Doxorubicin—pancreatic cancer	9.84e-05	0.000635	CcSEcCtD
Azelastine—Pain—Doxorubicin—pancreatic cancer	9.84e-05	0.000635	CcSEcCtD
Azelastine—Abdominal pain—Epirubicin—pancreatic cancer	9.83e-05	0.000634	CcSEcCtD
Azelastine—Body temperature increased—Epirubicin—pancreatic cancer	9.83e-05	0.000634	CcSEcCtD
Azelastine—Feeling abnormal—Doxorubicin—pancreatic cancer	9.48e-05	0.000612	CcSEcCtD
Azelastine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	9.41e-05	0.000607	CcSEcCtD
Azelastine—Hypersensitivity—Epirubicin—pancreatic cancer	9.16e-05	0.000591	CcSEcCtD
Azelastine—Body temperature increased—Doxorubicin—pancreatic cancer	9.1e-05	0.000587	CcSEcCtD
Azelastine—Abdominal pain—Doxorubicin—pancreatic cancer	9.1e-05	0.000587	CcSEcCtD
Azelastine—Asthenia—Epirubicin—pancreatic cancer	8.92e-05	0.000576	CcSEcCtD
Azelastine—Pruritus—Epirubicin—pancreatic cancer	8.8e-05	0.000568	CcSEcCtD
Azelastine—Diarrhoea—Epirubicin—pancreatic cancer	8.51e-05	0.000549	CcSEcCtD
Azelastine—Hypersensitivity—Doxorubicin—pancreatic cancer	8.48e-05	0.000547	CcSEcCtD
Azelastine—Asthenia—Doxorubicin—pancreatic cancer	8.26e-05	0.000533	CcSEcCtD
Azelastine—Dizziness—Epirubicin—pancreatic cancer	8.22e-05	0.00053	CcSEcCtD
Azelastine—Pruritus—Doxorubicin—pancreatic cancer	8.14e-05	0.000525	CcSEcCtD
Azelastine—Vomiting—Epirubicin—pancreatic cancer	7.91e-05	0.00051	CcSEcCtD
Azelastine—Diarrhoea—Doxorubicin—pancreatic cancer	7.87e-05	0.000508	CcSEcCtD
Azelastine—Rash—Epirubicin—pancreatic cancer	7.84e-05	0.000506	CcSEcCtD
Azelastine—Dermatitis—Epirubicin—pancreatic cancer	7.83e-05	0.000505	CcSEcCtD
Azelastine—Headache—Epirubicin—pancreatic cancer	7.79e-05	0.000503	CcSEcCtD
Azelastine—Dizziness—Doxorubicin—pancreatic cancer	7.61e-05	0.000491	CcSEcCtD
Azelastine—Nausea—Epirubicin—pancreatic cancer	7.39e-05	0.000476	CcSEcCtD
Azelastine—Vomiting—Doxorubicin—pancreatic cancer	7.32e-05	0.000472	CcSEcCtD
Azelastine—Rash—Doxorubicin—pancreatic cancer	7.26e-05	0.000468	CcSEcCtD
Azelastine—Dermatitis—Doxorubicin—pancreatic cancer	7.25e-05	0.000468	CcSEcCtD
Azelastine—Headache—Doxorubicin—pancreatic cancer	7.21e-05	0.000465	CcSEcCtD
Azelastine—Nausea—Doxorubicin—pancreatic cancer	6.83e-05	0.000441	CcSEcCtD
Azelastine—CYP1A2—Metabolism—DPYD—pancreatic cancer	9.09e-06	0.000179	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—PIK3CB—pancreatic cancer	9.05e-06	0.000179	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—PIK3CB—pancreatic cancer	9.03e-06	0.000178	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—PIK3CA—pancreatic cancer	8.93e-06	0.000176	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—APOE—pancreatic cancer	8.87e-06	0.000175	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	8.87e-06	0.000175	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—TYMP—pancreatic cancer	8.85e-06	0.000175	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—TYMS—pancreatic cancer	8.8e-06	0.000174	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	8.79e-06	0.000173	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—SMAD4—pancreatic cancer	8.77e-06	0.000173	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—CXCL8—pancreatic cancer	8.7e-06	0.000172	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—CXCL8—pancreatic cancer	8.67e-06	0.000171	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—STK11—pancreatic cancer	8.66e-06	0.000171	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—TP53—pancreatic cancer	8.64e-06	0.00017	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	8.63e-06	0.00017	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—TYMS—pancreatic cancer	8.62e-06	0.00017	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—TYMS—pancreatic cancer	8.6e-06	0.00017	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CD44—pancreatic cancer	8.58e-06	0.000169	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—HES1—pancreatic cancer	8.56e-06	0.000169	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	8.54e-06	0.000168	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	8.4e-06	0.000166	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CD44—pancreatic cancer	8.37e-06	0.000165	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	8.32e-06	0.000164	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TERT—pancreatic cancer	8.28e-06	0.000163	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—HRAS—pancreatic cancer	8.27e-06	0.000163	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	8.24e-06	0.000163	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—GCG—pancreatic cancer	8.22e-06	0.000162	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—PIK3CB—pancreatic cancer	8.2e-06	0.000162	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	8.13e-06	0.00016	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—TYMS—pancreatic cancer	8.13e-06	0.00016	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GCG—pancreatic cancer	8.03e-06	0.000158	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CG—pancreatic cancer	8.01e-06	0.000158	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—HIF1A—pancreatic cancer	7.92e-06	0.000156	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TSC2—pancreatic cancer	7.9e-06	0.000156	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CD44—pancreatic cancer	7.89e-06	0.000156	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—CXCL8—pancreatic cancer	7.88e-06	0.000155	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CD44—pancreatic cancer	7.82e-06	0.000154	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—APOE—pancreatic cancer	7.73e-06	0.000153	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—STK11—pancreatic cancer	7.73e-06	0.000152	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PPARG—pancreatic cancer	7.73e-06	0.000152	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	7.66e-06	0.000151	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	7.59e-06	0.00015	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—KDR—pancreatic cancer	7.58e-06	0.000149	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GCG—pancreatic cancer	7.56e-06	0.000149	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—STK11—pancreatic cancer	7.55e-06	0.000149	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	7.51e-06	0.000148	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TERT—pancreatic cancer	7.5e-06	0.000148	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GCG—pancreatic cancer	7.5e-06	0.000148	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—TYMS—pancreatic cancer	7.45e-06	0.000147	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—AKT1—pancreatic cancer	7.3e-06	0.000144	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	7.26e-06	0.000143	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NFKBIA—pancreatic cancer	7.21e-06	0.000142	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—HIF1A—pancreatic cancer	7.17e-06	0.000141	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—APOE—pancreatic cancer	7.16e-06	0.000141	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TSC2—pancreatic cancer	7.15e-06	0.000141	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NOTCH1—pancreatic cancer	7.14e-06	0.000141	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GLP1R—pancreatic cancer	7.13e-06	0.000141	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—STK11—pancreatic cancer	7.11e-06	0.00014	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—STK11—pancreatic cancer	7.05e-06	0.000139	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CD—pancreatic cancer	7.04e-06	0.000139	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—DPYD—pancreatic cancer	7.02e-06	0.000138	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—APOE—pancreatic cancer	7.01e-06	0.000138	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—APOE—pancreatic cancer	7e-06	0.000138	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—APOE—pancreatic cancer	7e-06	0.000138	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CG—pancreatic cancer	6.98e-06	0.000138	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—NRAS—pancreatic cancer	6.98e-06	0.000138	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—EGF—pancreatic cancer	6.9e-06	0.000136	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KDR—pancreatic cancer	6.86e-06	0.000135	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CD44—pancreatic cancer	6.68e-06	0.000132	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	6.66e-06	0.000131	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—TYMS—pancreatic cancer	6.65e-06	0.000131	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.62e-06	0.00013	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—APOE—pancreatic cancer	6.61e-06	0.00013	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	6.54e-06	0.000129	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NFKBIA—pancreatic cancer	6.52e-06	0.000129	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—TYMS—pancreatic cancer	6.49e-06	0.000128	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	6.48e-06	0.000128	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NOTCH1—pancreatic cancer	6.46e-06	0.000127	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CG—pancreatic cancer	6.46e-06	0.000127	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GCG—pancreatic cancer	6.41e-06	0.000126	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—EGFR—pancreatic cancer	6.36e-06	0.000125	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CG—pancreatic cancer	6.33e-06	0.000125	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CG—pancreatic cancer	6.32e-06	0.000125	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—NRAS—pancreatic cancer	6.32e-06	0.000125	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	6.31e-06	0.000125	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.26e-06	0.000123	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—EGF—pancreatic cancer	6.25e-06	0.000123	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PPARG—pancreatic cancer	6.23e-06	0.000123	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CD—pancreatic cancer	6.14e-06	0.000121	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CB—pancreatic cancer	6.13e-06	0.000121	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—TYMS—pancreatic cancer	6.12e-06	0.000121	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PPARG—pancreatic cancer	6.11e-06	0.00012	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PPARG—pancreatic cancer	6.09e-06	0.00012	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PTGS2—pancreatic cancer	6.08e-06	0.00012	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.08e-06	0.00012	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—TYMS—pancreatic cancer	6.06e-06	0.00012	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—APOE—pancreatic cancer	6.06e-06	0.000119	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—STK11—pancreatic cancer	6.02e-06	0.000119	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—KRAS—pancreatic cancer	6.01e-06	0.000118	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CG—pancreatic cancer	5.96e-06	0.000118	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PPARG—pancreatic cancer	5.76e-06	0.000114	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—EGFR—pancreatic cancer	5.76e-06	0.000114	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.74e-06	0.000113	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CD—pancreatic cancer	5.68e-06	0.000112	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.65e-06	0.000112	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CD—pancreatic cancer	5.56e-06	0.00011	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CD—pancreatic cancer	5.55e-06	0.00011	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	5.55e-06	0.000109	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—PIK3CA—pancreatic cancer	5.52e-06	0.000109	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.5e-06	0.000109	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	5.47e-06	0.000108	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—KRAS—pancreatic cancer	5.44e-06	0.000107	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—APOE—pancreatic cancer	5.41e-06	0.000107	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CB—pancreatic cancer	5.35e-06	0.000105	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PTEN—pancreatic cancer	5.3e-06	0.000105	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—APOE—pancreatic cancer	5.28e-06	0.000104	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PPARG—pancreatic cancer	5.28e-06	0.000104	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	5.24e-06	0.000103	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—TYMS—pancreatic cancer	5.18e-06	0.000102	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CD44—pancreatic cancer	5.16e-06	0.000102	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CXCL8—pancreatic cancer	5.14e-06	0.000101	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.12e-06	0.000101	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—HRAS—pancreatic cancer	5.11e-06	0.000101	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—PIK3CA—pancreatic cancer	5e-06	9.85e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—APOE—pancreatic cancer	4.97e-06	9.81e-05	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—AKT1—pancreatic cancer	4.97e-06	9.79e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CB—pancreatic cancer	4.95e-06	9.76e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GCG—pancreatic cancer	4.94e-06	9.75e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—APOE—pancreatic cancer	4.93e-06	9.73e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CASP3—pancreatic cancer	4.92e-06	9.7e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PTGS2—pancreatic cancer	4.9e-06	9.67e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	4.88e-06	9.63e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CB—pancreatic cancer	4.85e-06	9.56e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CB—pancreatic cancer	4.84e-06	9.55e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	4.84e-06	9.54e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	4.81e-06	9.48e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PTGS2—pancreatic cancer	4.8e-06	9.47e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PTGS2—pancreatic cancer	4.79e-06	9.45e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CCND1—pancreatic cancer	4.79e-06	9.44e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CG—pancreatic cancer	4.76e-06	9.4e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	4.74e-06	9.35e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PPARG—pancreatic cancer	4.71e-06	9.29e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.67e-06	9.21e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CXCL8—pancreatic cancer	4.65e-06	9.18e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	4.65e-06	9.17e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—STK11—pancreatic cancer	4.65e-06	9.17e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—HRAS—pancreatic cancer	4.62e-06	9.12e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	4.62e-06	9.11e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PPARG—pancreatic cancer	4.6e-06	9.07e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	4.57e-06	9.01e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PTGS2—pancreatic cancer	4.53e-06	8.93e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	4.51e-06	8.89e-05	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—AKT1—pancreatic cancer	4.49e-06	8.86e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	4.49e-06	8.85e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CASP3—pancreatic cancer	4.45e-06	8.78e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	4.45e-06	8.78e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CCND1—pancreatic cancer	4.33e-06	8.55e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PPARG—pancreatic cancer	4.33e-06	8.54e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PPARG—pancreatic cancer	4.3e-06	8.47e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	4.29e-06	8.46e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	4.29e-06	8.46e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	4.29e-06	8.45e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PTEN—pancreatic cancer	4.28e-06	8.43e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—APOE—pancreatic cancer	4.21e-06	8.31e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MMP9—pancreatic cancer	4.21e-06	8.3e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	4.19e-06	8.26e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PTEN—pancreatic cancer	4.19e-06	8.26e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CD—pancreatic cancer	4.19e-06	8.26e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PTEN—pancreatic cancer	4.18e-06	8.25e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PTEN—pancreatic cancer	4.18e-06	8.24e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	4.17e-06	8.23e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTGS2—pancreatic cancer	4.15e-06	8.19e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	4.13e-06	8.15e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	4.12e-06	8.13e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	4.08e-06	8.05e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—TYMS—pancreatic cancer	4e-06	7.89e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.99e-06	7.87e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PTEN—pancreatic cancer	3.95e-06	7.79e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	3.95e-06	7.78e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	3.91e-06	7.72e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—SRC—pancreatic cancer	3.88e-06	7.65e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	3.84e-06	7.57e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	3.83e-06	7.56e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	3.8e-06	7.5e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	3.78e-06	7.45e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	3.76e-06	7.41e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—STAT3—pancreatic cancer	3.74e-06	7.38e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	3.74e-06	7.38e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CA—pancreatic cancer	3.74e-06	7.37e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NRAS—pancreatic cancer	3.73e-06	7.36e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTGS2—pancreatic cancer	3.71e-06	7.31e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PPARG—pancreatic cancer	3.67e-06	7.24e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CB—pancreatic cancer	3.65e-06	7.2e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTEN—pancreatic cancer	3.62e-06	7.14e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTGS2—pancreatic cancer	3.62e-06	7.13e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	3.55e-06	7e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MYC—pancreatic cancer	3.48e-06	6.86e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	3.47e-06	6.84e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	3.44e-06	6.78e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	3.41e-06	6.73e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTGS2—pancreatic cancer	3.41e-06	6.72e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—EGFR—pancreatic cancer	3.4e-06	6.71e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTGS2—pancreatic cancer	3.38e-06	6.66e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	3.34e-06	6.59e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	3.26e-06	6.43e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—APOE—pancreatic cancer	3.25e-06	6.41e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTEN—pancreatic cancer	3.23e-06	6.37e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KRAS—pancreatic cancer	3.21e-06	6.34e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTEN—pancreatic cancer	3.15e-06	6.22e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	3.15e-06	6.22e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—AKT1—pancreatic cancer	3.05e-06	6.02e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CA—pancreatic cancer	3.02e-06	5.95e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	3.02e-06	5.95e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTEN—pancreatic cancer	2.97e-06	5.86e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CA—pancreatic cancer	2.96e-06	5.83e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	2.95e-06	5.82e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	2.95e-06	5.82e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTEN—pancreatic cancer	2.95e-06	5.81e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	2.94e-06	5.79e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	2.91e-06	5.75e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTGS2—pancreatic cancer	2.89e-06	5.69e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TP53—pancreatic cancer	2.86e-06	5.63e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.83e-06	5.59e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	2.79e-06	5.49e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—HRAS—pancreatic cancer	2.73e-06	5.39e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	2.66e-06	5.25e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.58e-06	5.09e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	2.55e-06	5.04e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTEN—pancreatic cancer	2.52e-06	4.97e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—AKT1—pancreatic cancer	2.46e-06	4.86e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—AKT1—pancreatic cancer	2.41e-06	4.76e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—AKT1—pancreatic cancer	2.41e-06	4.75e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—AKT1—pancreatic cancer	2.41e-06	4.75e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	2.28e-06	4.5e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—AKT1—pancreatic cancer	2.28e-06	4.49e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.25e-06	4.44e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.23e-06	4.39e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.23e-06	4.39e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.1e-06	4.14e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—AKT1—pancreatic cancer	2.09e-06	4.12e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	2.08e-06	4.1e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.94e-06	3.83e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—AKT1—pancreatic cancer	1.86e-06	3.67e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—AKT1—pancreatic cancer	1.82e-06	3.59e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.78e-06	3.5e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.71e-06	3.38e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—AKT1—pancreatic cancer	1.7e-06	3.35e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.45e-06	2.86e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.37e-06	2.7e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.12e-06	2.21e-05	CbGpPWpGaD
